http://rdf.ncbi.nlm.nih.gov/pubchem/patent/IE-53804-B1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_97a285d8ecd0184a7e5d89a1e4e07997 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-08 |
filingDate | 1982-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 1989-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | IE-53804-B1 |
titleOfInvention | N-methyl-d-glucamine salt |
abstract | Treatment of the antiallergic agent 3,4-dihydro-5-methyl-6-(2-methylpropyl)-4-oxothieno[2,3-d]pyrimidine-2 -carboxylic acid with N-methyl-D-glucamine gives a salt with improved solubility. Solutions of this salt have pH values in a range acceptable for topical formulations. Additionally, solutions of the subject salt exhibit good stability which can be demonstrated by retention of potency. The salt is comprised of a 1:1 molecular ratio of the glucamine base to the acid. |
priorityDate | 1981-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 35.